Obesity and insulin resistance enjoy a complex relationship that gives rise to a range of metabolic disorders, including type 2 diabetes, dyslipidemia and coagulation disorders. Teasing apart this relationship could yield new therapies to treat some of these conditions and two new reports point to the adipocyte-secreted protein, adiponectin, as a new molecular target.